Gilead Sciences, Inc. (NASDAQ:GILD) was upgraded by research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Thursday.

GILD has been the subject of a number of other reports. Jefferies Group LLC reissued a “hold” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 11th. BMO Capital Markets reissued an “outperform” rating and set a $82.00 price target (up from $72.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Leerink Swann reissued a “market perform” rating on shares of Gilead Sciences in a research note on Thursday, June 22nd. BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Finally, J P Morgan Chase & Co reissued an “overweight” rating and set a $82.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 4th. Ten research analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $83.06.

Gilead Sciences (GILD) traded up 3.04% on Thursday, hitting $85.47. 13,147,848 shares of the company were exchanged. The stock has a 50 day moving average price of $75.50 and a 200 day moving average price of $69.60. The firm has a market cap of $111.62 billion, a price-to-earnings ratio of 9.28 and a beta of 1.19. Gilead Sciences has a one year low of $63.76 and a one year high of $85.62.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. During the same period in the previous year, the firm posted $3.08 earnings per share. The company’s revenue was down 8.2% on a year-over-year basis. On average, equities research analysts forecast that Gilead Sciences will post $8.74 EPS for the current fiscal year.

WARNING: “Gilead Sciences, Inc. (GILD) Upgraded to “Strong-Buy” at ValuEngine” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/07/gilead-sciences-inc-gild-upgraded-to-strong-buy-at-valuengine.html.

In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the company’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the sale, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the sale, the insider now directly owns 3,199,969 shares in the company, valued at $227,197,799. The disclosure for this sale can be found here. Insiders have sold 414,999 shares of company stock worth $32,335,540 over the last ninety days. Insiders own 1.30% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares during the period. Dubuque Bank & Trust Co. raised its position in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 267 shares during the period. Penserra Capital Management LLC raised its position in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. raised its position in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 624 shares during the period. Finally, American Beacon Advisors Inc. bought a new position in shares of Gilead Sciences in the first quarter valued at about $143,000. 74.05% of the stock is currently owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.